TENAX THERAPEUTICS, INC. (TENX): Nasdaq/NYSE listing notice — Tenax Therapeutics gets Nasdaq extension to March 25, 2024 for $1 bid price rule

TENAX THERAPEUTICS, INC.

Nasdaq granted extension through March 25, 2024 to regain compliance with $1.00 minimum bid price (Rule 5550(a)(2)).
Original compliance period ended Sept. 25, 2023; extension provides six additional months.
If bid price closes at $1.00+ for ten consecutive days, Nasdaq will confirm compliance.
If not compliant by March 25, 2024, Nasdaq will issue delisting notice; company may appeal.
Company evaluating options including reverse stock split; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TENAX THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 28, 2023, Tenax Therapeutics, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted the Company’s request for an extension through March 25, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before March 25, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company w

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-23-012433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.